Trailing-twelve-month (TTM) revenue is $252.72 Million with a year-over-year growth of +14.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $61,250,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $61,605,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-04 |
| Q1 FY2026Period ended 2026-03-31 | $59,362,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q2 FY2026Period ended 2026-06-30 | $70,508,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $252,725,000 |
Current P/S: $587,030,538 market capitalization ÷ $252,725,000 TTM revenue = 2.32x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:35:12.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $70.51M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:37:03.884Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| ACL Reconstruction and Other | $3M | $4M | $4M | $4M | $4M | N/A |
| Spine | $21M | $28M | $33M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Non-US | $8M | $20M | $30M | $38M | $44M | $50M |
| UNITED STATES | $63M | $78M | $92M | $111M |
$252.72M
$252.72 Million
+14.49%
vs. $220.74M a year ago (TTM)
+23.14%
5 Year compound annual growth rate
1 Year
+14.49%
3 Year
+22.61%
5 Year
+23.14%
10 Year
+22.52%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $236.35M | +$31.62M | +15.45% |
| 2024 | $204.73M | +$55.99M | +37.65% |
| 2023 | $148.73M | +$26.44M | +21.62% |
| 2022 | $122.29M | +$24.24M | +24.72% |
| 2021 | $98.05M | +$26.97M | +37.95% |
| 2020 |
TTM Growth
+14.49%
3-Year CAGR
+22.61%
5-Year CAGR
+23.14%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 38 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:37:03.884Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $55M |
| $66M |
| Sports Medicine And Other | N/A | N/A | N/A | N/A | N/A | $4M |
|---|
| Trauma and Deformity | $48M | $66M | $85M | $107M | $145M | $166M |
|---|
| $186M |
| $71.08M |
| ($1.47M) |
| (2.03%) |
| 2019 | $72.55M | +$14.99M | +26.05% |
| 2018 | $57.56M | +$11.94M | +26.17% |
| 2017 | $45.62M | +$8.32M | +22.31% |
| 2016 | $37.30M | +$6.29M | +20.30% |
